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Abstract
Articular cartilage injuries caused by traumatic/mechanical progressive degeneration 
result in joint pain, swelling, the consequent loss of joint function, and eventually osteo-
arthritis. Articular tissue possesses a poor ability to regenerate that further complicates 
the therapeutic approaches. Mesenchymal stem cells (MSCs) have emerged as a promis-
ing alternative treatment. Recently, it has been reported that a wide variety of strategies 
ranging from merely using cells in the injured area to employ biofunctional substitutes in 
which cells are harmonizing with scaffolding and growth factors to create an engineered 
cartilage tissue. 
This chapter reviews the state-of the-art in cartilage tissue engineering focused on tis-
sue engineering approaches designed to recapitulate the native development of carti-
lage and its tridimensional structure as an osteochondral unit. Since the production of 
hypertrophied tissue is one of the most critical challenges to overcome in chondral tissue 
regeneration, here we show new strategies to minimize hypertrophy in cartilage. Finally, 
the efficacy and safety of different treatments of cartilage in current clinical trials will be 
discussed. 
While the framework provides new features and benefits concerning the strategies for 
articular tissue regeneration, this chapter presents a set of tools to improve approaches to 
orthopedic regenerative medicine based on the use of MSCs.
Keywords: MSCs, MSCs-subpopulations, cartilage regeneration, cartilage tissue 
engineering, hypertrophy
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1. Introduction
The chondrocytes are the only cells found in cartilage. The chondrocytes demonstrate dis-
tinctive properties such as being metabolically active in order to maintain the renewal of the 
extracellular matrix (ECM) by synthesizing collagens, proteoglycans, hyaluronic acid, and 
glycoproteins. Restoration of the cartilage damage is still challenging for orthopedic medicine 
due to its poor ability to regenerate [1].
Mesenchymal stem cells (MSCs) have potential applications in tissue engineering, and regen-
erative medicine represents an attractive option for repairing lesions in cartilage. Stem cell–
based therapies that harmonize with tissue-engineering technologies, and biomaterials are 
vital for the continuous advance of cartilage regenerative medicine [2, 3].
Once the relationship between structure function in normal and damaged tissues is under-
stood and the development of biological substitutes for the repair or regeneration can be 
reached. To develop a biological substitute, tissue engineering uses scaffolds, cells, and 
growth factors. Each of these elements alone is able to promote tissue regeneration, but com-
posites fabricated in combination would be more effective [4, 5].
The objective of the present chapter is, therefore, to describe the cellular and molecular frame-
work in which chondrocyte differentiation develops and the articular tissue responds to the 
injury.
The maintenance of the chondrogenic phenotype during in vitro expansion and avoidance of 
hypertrophy of MSC-derived chondrocytes remains a challenge in cell-based strategies. Since 
chondrocyte differentiation is regulated by various signalling pathways, including fibroblast 
growth factor (FGF), transforming growth factor-β (TGF-β), and wingless/Int (WNT)/β-catenin, 
the role of these growth factors is analyzed. Furthermore, we show some strategies to mini-
mize hypertrophy in cartilage [6–8].
Even though an ideal protocol for cartilage regeneration is yet to be established, approaches 
involving cells, biomaterials, and technology of tissue engineering will advance firmly toward 
effective clinical application.
2. Cartilage tissue
Cartilage is a type of connective tissue whose function is to protect the bones of the diarthrodial 
joints from the frictional forces associated with the load and impact support [1]. Hyaline or artic-
ular cartilage is heterologous, with varying density and organization according to the depth of 
its zones [9]. Articular cartilage is predominantly avascular, aneural, and alymphatic, so the main 
route for nutrition is through synovial fluid and assisted by mechanical compression forces [10].
The articular cartilage forms a thin layer of tissue with variable thickness depending on the 
body location. In humans, it ranges from 1 to 4 mm depending on the joint [11]. This tissue has 
viscoelastic ability, giving it the characteristic of deforming in order to increase the total contact 
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surface with the consequent reduction of stress and increase the resistance to damage caused 
by applied loads. This function depends on the organization of the macromolecules in the 
extracellular matrix, particularly the arrangement and orientation of the collagen fibers [12].
Articular cartilage possesses a coefficient of friction between 0.002 and 0.02; the quality of the 
synovial fluid, the elastic deformation of the cartilage, and the effusion of the liquid from it 
are the factors able to decrease it. There are also factors that increase the coefficient of friction, 
such as alteration in the continuity at the surface of the cartilage (fibrillation) [13].
2.1. Chondrocytes
Cartilage consists of a single type of specialized cells called chondrocytes, representing appro-
ximately 5–10% of the tissue [14]; chondrocytes are embedded and clustered in the extracel-
lular matrix (ECM) secreted by themselves (Figure 1A). Its function is influenced by changes 
in the ECM itself, as much as by changes in cell membrane pressure, age, and certain growth 
factors. These cells depolymerize and eliminate the ECM to enlarge their lacunae, a process 
featured in the endochondral ossification [13]. They are also present in isolation or organized 
in isogenic groups, depending on their metabolic activity, i.e., the cells that have just divided 
are active chondrocytes possessing a very large Golgi apparatus and a basophilic cytoplasm, 
which means that it can be stained with basic stains with net positive charge such as hema-
toxylin. These characteristics indicate that a protein synthesis is being performed and are 
initially located in the same lacunae, but as they secrete new intercellular matrix, they are 
separated; on the contrary, initial chondrocytes with low or no activity have a clear cytoplasm 
and a small Golgi apparatus [13].
2.2. Extracellular matrix
More than 98% of the articular cartilage corresponds to the ECM. The extracellular matrix is a 
dynamic network of macromolecules self-assembled. It is composed of water, gases, metabo-
lites, cations and predominantly of collagens, noncollagenous glycoproteins, hyaluronan, and 
proteoglycans. ECM is able to regulate cell behavior influencing its proliferation and maturation 
processes. Therefore, it is not only scaffolding for chondrocytes but also functioning as a reser-
voir for growth factors and cytokines and modulates the cell activation state (Figure 1A) [13].
2.2.1. Water
The water occupies between 60 and 80% of the ECM volume; its function is to allow the defor-
mation of the cartilage in response to stress, and it is also important for cartilage nutrition 
and joint lubrication. Approximately 30% of the water is contained in the intrafibrillar space 
within the collagen; however, a small percentage fills the intracellular space. The rest is con-
centrated in the pore space of the matrix. Interestingly, the ability of the articular cartilage to 
withstand significant loads comes from the frictional resistance to water flow and the pres-
surization of water within the matrix. When the amount of water increases up to 90%, as in 
the osteoarthritis (OA), it causes increased permeability, which in turn causes a decrease in 
resistance and compromises elastic abilities [13].




Collagen is the most abundant structural macromolecule in ECM, and it makes up about 60% 
of the dry weight of cartilage. Collagen types present in cartilage are I, II, IV, V, VI, IX, and 
XI; however, type II collagen represents 90–95% of the total amount. Type II collagen forms 
fibrils, and fibers intertwines with proteoglycan, while the minor collagens stabilize the fibril 
Figure 1. Components of ECM and 3D structure of the articular cartilage. (A) Model of extracellular matrix proteins 
showing their interaction with each other: collagens (mostly type II collagen); proteoglycan monomers, GAGs as 
aggrecan, and chondroitin sulphate covalently bound to the core protein. The proteoglycan monomers are assembled 
onto hyaluronic acid to form aggregates of proteoglycans. (B) The 3D organization of normal articular cartilage: the four 
areas of the cartilage are highlighted. The superficial zone, where flattened chondrocytes are located; the middle zone 
containing elongated chondrocytes; the deep zone, where the chondrocytes are arranged in columns and at the bottom, 
the calcified zone. (A) is modified from Izadifar et al. [15], and (B) from Minas et al. [16].
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network. Collagen X alone is present in osteochondral ossification phases and is therefore 
associated with cartilage calcification. Collagen VI is thought to form hexagonal nets in the 
vicinity of cells where it can bind to collagen II fibrils through matrilin-4, and biglycan never-
theless can be found in OA processes [17].
2.2.3. Proteoglycans
Proteoglycans (PGs) represent 10–15% of the ECM and are the main noncollagenous proteins 
present in cartilage. These macromolecules secreted by chondrocytes are responsible for the 
compression of cartilage. PGs are composed of one or more linear glycosaminoglycan (GAGs) 
chains covalently attached. The most frequent GAG is chondroitin sulfate (of which there 
are two subtypes, chondroitin-4-sulfate and chondroitin-6-sulfate), then keratan sulfate (or 
keratan sulfate or keratin sulfate), and dermatan sulfate. GAGs bind to a protein core, thus 
structuring the aggrecan. These aggrecans are bound by hyaluronic acid-binding proteins (a 
nonsulfated GAG) to form aggregates of PGs. It is important to mention that chondroitin-
4-sulfate decreases over the years, whereas chondroitin-6-sulfate remains constant over the 
years, on the other hand, keratan sulfate and dermatan sulfate tend to increase with age. The 
half-life of PGs is 3 months, having the ability to retain water being responsible for the porous 
structure of cartilage [17].
Aggrecan occupies the interfibrillar space of the cartilage ECM and gives cartilage its osmotic 
properties, a critical feature to its ability to resist compressive loads [17].
The nonaggregating proteoglycans decorin, biglycan, and fibromodulin are also able to inter-
act with collagen. These molecules differ from glycosaminoglycan in composition and func-
tion. Decorin and fibromodulin interact with the type II collagen fibrils and have a role in 
fibrillogenesis and interfibril interactions, whereas biglycan mainly interacts with collagen VI 
(Figure 1A) [18].
2.3. Extracellular glycoproteins
Among these are anchorine CII, fibronectin, laminin, and integrins. Their functions are to 
connect to the chondrocytes with the ECM, whereas integrins are the most important since 
they are able to interact with cellular receptors and influence migration, proliferation, and 
differentiation of chondrocytes [19].
Cartilage usually has protease inhibitors that help in the continuous renewal of the ECM con-
stituent. The composition of ECM varies depending on the cartilage layer and the proximity 
to the chondrocytes, in this way, PGs rich in keratan-sulfate accumulate in the internal ECM, 
whereas in the territorial ECM, PGs rich in chondroitin sulfate are abundantly found.
Integrins into focal adhesions contribute to the activation of signaling pathways in the cell, 
promoting changes in cell survival, proliferation, and gene expression [20]. In vitro studies 
demonstrate that chondrocytes may interact with various proteins of the ECM such as fibro-
nectin, laminin, vitronectin, osteopontin, bone sialoprotein II, and collagen types I, II, and VI 
through different integrins [21, 22].
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2.4. Tridimensional structure of the articular cartilage
Till this point, we have reviewed the cellular and molecular components of the articular tis-
sue, but how are they connected to each other?
The articular cartilage has a complex three-dimensional structure. Chondrocytes, collagen 
fibers, and ECM allow separate articular cartilage into various zones: the superficial zone, 
the middle zone, the deep zone, and the calcified zone (Figure 1B). The space between these 
zones allows in turn identifying three regions: the pericellular region, the territorial region, 
and the interterritorial region.
The superficial zone is thin and protects deeper layers from shear stresses. Mainly composed of 
types II and IX collagen packed tightly and aligned parallel to the articular surface (Figure 1B), 
contains flattened chondrocytes, which are in contact with synovial fluid. This zone is respon-
sible for the tensile properties of cartilage. Below the superficial zone, the middle (transitional) 
zone is found, representing a bridge between the superficial and deep zones. The middle zone 
contains spherical chondrocytes at low density, proteoglycans, and thicker collagen fibrils. 
The middle zone is responsible for resistance to compressive forces. The deep zone provides 
the highest resistance to compressive forces. In the deep zone are found the largest diameter 
collagen fibrils in a radial arrangement and a low quantity of water. The chondrocytes are 
organized in columnar orientation, parallel to the collagen fibers and perpendicular to the 
joint line. Finally, the calcified layer of hypertrophic chondrocytes attaches the cartilage to the 
bones through anchoring the collagen fibrils of the deep zone to subchondral bone. The tide-
mark discriminate the deep zone from the calcified cartilage.
3. Cartilage injuries and osteoarthritis
Articular cartilage injuries are able to stimulate significant musculoskeletal morbidity in 
young and in aging patient populations. Restoration of joint damage to date represents a 
major challenge for medicine since they cannot heal spontaneously, and over time can also 
lead to the development of osteoarthritis.
The grading of articular cartilage lesions is performed through instrumented palpation of the 
lesion and via direct observation by arthroscopy [23, 24]. The most complete grading system 
is established by the International Cartilage Repair Society (ICRS) [25]. The ICRS grading sys-
tem is based on the depth of the lesion and the degree to which subchondral bone is involved 
and classified the lesion as follows: Grade 0 for a normal joint; Grade 1 for nearly normal, 
featured by superficial lesions, soft indentation, and/or superficial fissures and cracks; Grade 
2 for abnormal lesions extending down to <50% of cartilage depth; Grade 3 for severely abnor-
mal lesions where cartilage defects are extending down to >50% of cartilage depth as well as 
down to calcified layer and down to but not through the subchondral bone; and Grade 4 for 
severely abnormal lesions where blisters are included [25].
Articular cartilage has limited ability for intrinsic repair. The injured chondrocytes (by a super-
ficial or partial-thickness injuries) since early stages have a defective metabolic capacity and 
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unable to maintain the normal PG concentration. This triggers other modifications in the tis-
sue, such as increased tissue hydration and fibrillar disorganization of the collagen [26, 27]. 
These changes favor an increased transmission force to the subchondral bone. Exceeding the 
capacity of the subchondral bone makes the impact on the damaged cartilage even greater. 
In response to the events, chondrocytes proliferate, and thus production of matrix molecules 
at the site of injury increases; however, the new matrix fails to restore the native surface [26]. 
When the injury reaches subchondral bone (full-thickness injuries), the inflow of pluripotent 
marrow elements is observed [28]. The migrating mesenchymal stem cells produce type I col-
lagen fibers to fill the full-thickness defect with fibrocartilage. Fibrocartilage fails to provide 
the necessary functions needed by the articular cartilage [29].
The strategies for articular cartilage lesions treatment can be classified into palliative such as 
physiotherapy and systemic pain relief medications; reparative such as debridement, knee 
joint lavage, arthroscopic abrasion arthroplasty, microfracture, and marrow stimulation tech-
niques; restorative such as high tibial osteotomy, unicompartmental knee arthroplasty, and 
total knee arthroplasty; and transplantation such as osteochondral transplantation (osteo-
chondral grafting), mosaicplasty, and autologous chondrocyte transplantation [27, 30].
Osteoarthritis (OA) is a chronic joint disorder classified into primary and secondary according 
to the etiology. OA is characterized by the progressive breakdown of the articular cartilage like-
wise changes in the subchondral bone, synovium, and muscles [31]. In early-stage OA, remod-
eling and bone loss of both trabecular and cortical subchondral areas are enhanced, while 
late-stage OA is featured by remodeling and an increased subchondral plate densification [32].
Mesenchymal stem cells (MSCs) are a promising option for the treatment of OA. MSCs are multi-
potent progenitor cells with self-renewal abilities, high plasticity, and anti-inflammatory proper-
ties; moreover, the capability to differentiate into different lineages including chondrocytes [33].
Despite extensive preclinical research with promising results, because of its technical limita-
tions such as definition on the optimal cell source, processing, assembly with scaffolding, 
and administration modality, the use in patients is not yet overwhelming, and the design of a 
systematic procedure is still to be addressed [34, 35, 153, 154].
4. Cartilage tissue engineering
The application of cells into scaffolds, as tissue engineering do, makes cartilage regeneration 
strategies complex but allows to orchestrate the process efficiently [155]. Tissue engineer-
ing (TI) can be defined as the combined use of cells, biomaterials, and chemical factors to 
repair injured or diseased tissues. At the moment, it combines the contribution of cells that are 
placed on a scaffold, where the factors that accelerate its proliferation can be added; this com-
posite is then transplanted at the site of the lesion in order to achieve tissue regeneration [36].
TI has the potential to provide long-lasting solutions to tissue damage and tissue loss, and 
engineering cartilage is not an exception to this approach. In fact, due to its limited ability to 
self-repair, cartilage is an ideal candidate for tissue engineering.
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The critical point of the strategies based on TI is the expansion of cells in culture to be able 
to generate more cells for the production of tissue in vitro or for the implantation of cells in 
suspension or on scaffolds for regeneration of the tissue in vivo [37]. Another challenge to 
overcome regarding this strategy is to achieve the merging of the composite after implanta-
tion. The integration of the implanted tissue with the organ requires remodeling, degrada-
tion, and formation of new tissue. The remodeling of the implanted tissue is essential for its 
functionality [37].
TI makes possible the in vitro tissue synthesis, and then, the functional abilities of the com-
posite can be evaluated before implantation. The main disadvantage is the partial absence 
of physiological and mechanical stimuli during their formation, which does not allow an 
adequate cellular regulation and spatial development of the tissue, and the decrease of its 
mechanical quality is observed as a consequence.
In the past decades, the strategies were designed without considering the cartilage as a com-
plex tissue with a functionally that stratified three-dimensional structure. Nowadays, efforts 
are focused on achieving the landmarks in the process of cartilage formation with the devel-
opment of a multiphase implant that recapitulates the cartilage as an osteochondral unit [156].
Cartilage tissue engineering combines a cell source, biomaterials, and growth or differentia-
tion factors. Useful cell sources include autologous chondrocytes, minced autologous carti-
lage, and mesenchymal stem cells (from bone marrow, muscle, synovium, or adipose) [4, 6, 7, 
24–28]. Regarding scaffolds, they may be fabricated with natural (e.g., collagen) or synthetic 
materials and designed as monophasic (chondral phase) or multiphasic (imitating the osteo-
chondral unit) [6–8, 23, 38–41, 157, 158].
Chondroinductive growth factors are essentially members of the transforming growth factor-β 
(TGF-β) superfamily, some members of fibroblast growth factor (FGF) family and insulin-like 
growth factor-1 (IGF-1). These growth factors can be added to a culture medium to induce 
chondrogenic differentiation or through gene delivery, and, more recently, by nanoparticle 
delivery [4, 27, 29–32].
4.1. Cell source
Cell-based therapy is a biological therapy, involving the use of cells to develop new tissues or 
repair damage tissues. Therapies have been designed in order to generate a neocartilage in an 
attempt to offer the patients with chondral injuries an improvement in the quality of life or a 
long-lasting cure.
Autologous implantation of chondrocytes (ACT), intra-articular injection of meniscus with 
stem cells, and autologous matrix-induced chondrogenesis represent the current strategies 
for cartilage repairing by cell-based therapies. Furthermore, approaches using cell therapy 
with tissue engineering and biomaterials are increasing [42].
The optimal cell source for cartilage tissue engineering is not yet well established. The goal is 
to select a cell source that can be isolated by simple methods, are able to expand, and capable 
of being cultured to synthesize cartilage-specific molecules. The sources range from chondro-
cytes, fibroblasts, and stem cells to genetically modified cells [159–161].
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Although chondrocytes have been the most used at first since they are found in native carti-
lage and have been extensively studied, they currently do not represent the best option.
Likewise, fibroblasts are easily and abundantly obtained and under treatment with lactic acid, 
they can acquire a chondrogenic phenotype.
Furthermore, stem cells can be expanded through several passages maintaining the differ-
entiation potential. Additionally, all of these cells can be modified genetically to induce or 
enhance chondrogenesis. Adult MSCs are able to differentiate into osteoblasts, adipocytes, 
muscles, and chondrocytes and are, therefore, a suitable cellular source for tissue regenera-
tion. Recent evidence indicates that there is great variability in the ability of differentiation 
between stem cells from specific tissues.
4.1.1. Chondrocytes
To perform autologous chondrocytes implantation, a full-thickness sample from a low-weight-
bearing region of the joint is taken by biopsy during a first arthroscopic operation to collect a 
chondrocyte population.
The recovered tissue is enzymatically treated to isolate chondrocytes, which are then ex vivo 
expanded under conditions that preserve cell viability till yielding ~12–48 million cells [43].
During a second operation, the chondrocytes are implanted into the debrided cartilage defect. 
This technique avoids potential immune complications or viral infections from transplanting 
allogeneic cells or foreign materials [44]. Nevertheless, two operations are needed, and a long 
recovery time (6–12 months) is required to ensure neotissue maturation.
Several studies have shown that chondrocytes “dedifferentiate” into fibrochondrocytes in cul-
ture [45]. However, according to Martinez et al., they can redifferentiate and express chondro-
cytic markers after being cultured into a 3D in vitro culture system [46].
Moreover, ex vivo culturing of the chondrocytes reduced production of type II collagen and 
PGs upon expansion in monolayer culturing [47]. This process has been known as dedifferen-
tiation, so the analysis of different markers of chondrocytic maturity as BMP-2, FGFR-3, and 
COL2A1 is necessary to confirm a stable chondrocyte phenotype.
The growth and the expression of type II collagen have been assessed after autologous chondro-
cytes implantation to substantiate the expansion of chondrocytes. These markers were found 
ineffective in predicting the capacity of expanded cells to produce stable cartilage tissue [48].
Xenogeneic and allogeneic chondrocyte have been studied as alternative chondrocytes cell 
sources. However, these cells can be involved in the induction of immune responses and 
diseases transmission. Thus, more studies are needed to overcome such issues in the field of 
allogeneic and xenogeneic chondrocytes.
4.1.2. Mesenchymal stem cells
MSCs have higher proliferation rates than chondrocytes and possess a vast differentiation 
potential toward a chondrogenic, also they are easy to collect from several tissues, such as 
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adipose tissue, synovial membrane, and bone marrow. In addition, MSCs produces several 
extracellular matrix macromolecules involved in cartilage function, including fibronectin, 
collagen(s), PGs, and glycosylaminoglycans (GAGs), as well as a wide range of cytokines, 
growth factors, chemokines, and colony stimulating factors [49].
4.1.2.1. Bone marrow–derived MSCs
Bone marrow–derived stem cells (BM-MSCs) are one of the relevant stem cell choices for 
tissue engineering, and different studies have reported a potential of these cells for cartilage 
repair and as a treatment of the osteoarthritis. BM-MSCs can be differentiated into chondro-
cytes in a variety of culture conditions, usually involving induction with TGF-β and in a tridi-
mensional environment (e.g., cell pellets and micromasses). The addition of TGF-β enhances 
chondrogenesis; however, the degree of chondrogenesis depends on the culture method or 
scaffolding [50]. In addition to TGF-β, other growth factors as BMP-6 and IGF-1 during in vitro 
culture also affect chondrogenesis as evidenced by enhanced type II collagen and aggrecan 
expression and accumulation [51].
Coculture system with chondrocytes is another approach used to promote chondrocyte dif-
ferentiation of MSCs. Cell proliferation and positive expression of type II collagen have been 
observed, and this is due to growth factor secretions and cell-cell interactions as well as the 
microenvironment created by the chondrocytes [52].
Limitation on the use of BM-MSCs is the mechanical integrity of the matrix they produce 
which is poor in GAGs content. Moreover, in BM-MSCs undergoing chondrogenic induction, 
a high expression of COLX, MMP13, and ALP markers was observed by in vitro pellet culture; 
this profile frames a hypertrophic process. Likewise, stem cells derived from adipose tissue 
(AD-MSCs) were also associated with the development of hypertrophy, as demonstrated by 
type X collagen over-expression and up-regulation of ALP activity [53].
4.1.2.2. Adipose tissue–derived MSCs
Adipose tissue–derived MSCs (AD-MSCs) have a mesenchymal lineage as demonstrated by 
the expression of surface markers, such as CD105, CD73, and CD90, and posses the potential 
to differentiate into chondrocytes. Differentiation is achieved under a high density as micro-
mass cultures or embedded in scaffolds in the presence of TGF-β, ascorbate, and dexametha-
sone, especially in combination with a tridimensional culture environment [54].
Lai et al. analyze chondrogenic potential of human adipose–derived stem cells (hAD-MSCs) 
using three-dimension biomimetic hydrogels. In addition, the effect of TGF-β3 supplementa-
tion was also included. They demonstrated that in the presence of TGF-β3, the expression 
levels of aggrecan and type II collagen expression were significantly up-regulated. However, 
expression levels of type I- and X- collagen were also significantly enhanced, which indicates 
a fibrotic repair [55].
To overcome the fibrotic repair, Zhu et al. developed a strategy of programmed application 
of TGFβ3 and NSC23766 (a Rac1 inhibitor) to commit the hyaline cartilage differentiation of 
adipose-derived stem cells (AD-MSCs) for joint cartilage repair. The efficacy of AD-MSCs 
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with programmed application of TGFβ3 and Rac1 inhibitor for cartilage regeneration was 
analyzed in a rat model of osteochondral defects. The results showed that TGFβ3 promoted 
AD-MSCs chondro-lineage differentiation, and that the administration of NSC23766 after 7 
days postindcution prevented AD-MSC-derived chondrocytes from hypertrophy in vitro and 
in vivo (Figure 2) [56].
Figure 2. Chondrocyte differentiation from MSCs. Scheme showing the main transcription factors and growth factors 
involved in the production of extracellular matrix proteins in the articular cartilage.
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In vitro culture, using growth factors like FGF-2 and BMP-6, influences the chondrogenesis of 
AD-MSCs as they are able to generate matrix proteins with accumulation of sulfated-GAGs. 
The use of FGF-2 increases cell proliferation and chondrogenesis through up-regulation of 
FGF-R2 and Sox 9 [57]. Besides, BMP-6 enhances expression of aggrecan and type II collagen 
(Figure 2) [58].
4.1.2.3. Synovium-derived MSCs
In the pursuit for a healthy cartilage regeneration through autologous transplantation, it has 
been discovered that synovial can be a valuable source of SCs for the effective induction of 
chondrogenesis and the production of high-quality cartilage in vitro [59, 60] and in vivo [61].
Synovium-derived MSCs (SDSCs) have a more effective chondrogenic potential than stem 
cells from other sources. Sakaguchi et al. revealed that human SDSCs have greater expansion 
and chondrogenic ability in vitro than MSCs from classical sources as bone marrow, peri-
osteum, and adipose tissue. They also note that SDSCs generated larger pellets and a more 
structured ECM consistent with toluidine blue cartilage matrix staining, concluding that these 
are a superior source for chondrogenesis than AD-MSCs [62].
Extracellular matrix deposited by SDSCs overcomes two of the main problems related to the 
development and maturation of chondrocytes: dedifferentiation and chondrocyte redifferen-
tiation [63]. Both processes are beaten because the tissue engineered cartilage matrix secreted 
by SDSCs is rich in collagen-II and aggrecan but not collagen-I or collagen-X and is mechani-
cally similar to articular cartilage [64].
MSCs culture in general possesses inherent cell heterogeneity; however, for tissue engineer-
ing applications, it is imperative to start with a well-defined cell population, particularly, 
since it has been demonstrated that MSCs subpopulations are featured by a distinct regenera-
tion potential. In this regard, the isolation of subpopulations from SDSCs cultures has been 
reported using various surface markers in order to sort by flow cytometry.
Arufe et al. reported the isolation from SDSCs of a CD271+ subpopulation which showed high 
expression of SOX9, aggrecan, and COL2A1 at day 46 of chondrogenic induction; however, 
the expression of COL10A1 was observed [35, 65]. Meanwhile, the CD105+ subpopulation 
reached a homogeneous cellular culture, and it was shown that after a chondrogenic induc-
tion, the increase in SOX9 expression was efficiently accompanied by an extracellular matrix 
rich in type II collagen with no evidence of fibrocartilage [35, 66].
More recently, in 2013, another subpopulation with efficient chondrogenic potential was 
reported, and the CD73+CD39+ cell subpopulation showed higher expression levels of SOX9 
and a significantly greater chondrogenic potency than the CD73+CD39− cell subpopulation 
and the original SDSCs population [35, 67].
4.2. Growth and transcription factors in chondrocyte
Chondrocytes differentiation from MSCs, chondrocyte morphology maintenance, and carti-
lage matrix formation are processes driven by differentiation and growth factors. A number 
of extracellular signalling molecules and growth factors as members of the fibroblast growth 
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factor (FGF), hedgehog, transforming growth factor-β (TGF-β) and bone morphogenic pro-
tein (BMP), insulin-like growth factor (IGF), and wingless/Int (Wnt) glycoproteins are all key 
regulators of chondrocyte cell condensation and chondrogenic differentiation.
Cartilage formation begins by the condensation and then the differentiation of MSCs to 
prechondrocytes; thus, the cells first express types I and IIA collagen, and begins to syn-
thesize GAGs and adhesion-related proteins such as cadherin [68]. This cascade of events 
is in response to the effect of factors, such as some members of the TGF-β superfamily 
(TGF-β1, -β2, and -β3), which are able to induce the synthesis of fibronectin, tenascin, and 
syndecan [69].
As prechondrocytes, the expression of transcription factors as SOX9, L-SOX5, and SOX6 
became relevant until prechondrocytes reach the maturation stage and produce an ECM rich 
in collagen fibers (collagen types II, IX and XI) and PGs [70]. The main indicator of chondro-
cytes maturation is represented by type II collagen [71].
4.2.1. Insulin-like growth factor
Insulin-like growth factor (IGF) is a protein capable of regulating cell growth, differentiation, 
migration, and survival, and there are two types: IGF-1 and IGF-2. The activity of IGF-1 and 
IGF-2 (ligands) is collectively regulated by IGF-1R and IGF-2R (receptors), IGF-binding pro-
teases, and IGF-binding proteins.
IGF-1 plays an important role in cell proliferation; it is mainly expressed in the liver although 
also in brain, heart, lung, bone, placenta, and testes and also produced by chondrocytes [72] 
thus having an autocrine and/or paracrine regulation [73].
IGFs in the early stages of chondrogenic differentiation induce the proliferation of chondro-
cytes and stimulate the differentiation of MSCs into prechondrocytes. IGFs act through the 
type I receptor tyrosine kinase (IGF-1R) that triggers mitogenic activity, regulated by extra-
cellular kinase-kinase signals (MEK, ERK, and MAPK) and via the phosphatidylinositol 
3-kinase/Akt (PI3K/Akt) pathway. Several investigations in animal models in vivo demon-
strated that IGF significantly promotes the growth and matrix synthesis in articular cartilage 
and also improves the synthesis of proteoglycans and type II collagen [74].
4.2.2. The transforming growth factor-β
The transforming growth factor-β (TGF-β) is a superfamily of polypeptides and contains dif-
ferent factors, including TGF-β, inhibins, activins, and bone morphogenetic proteins (BMPs); 
the most promising for cartilage tissue engineering is TGF-β and bone morphogenetic pro-
teins (BMPs), highlighting BMP-2, GDF-5, and BMP-7 [75].
TGF-β generally induces differentiation of MSCs into chondrocytes, stimulates their prolif-
eration, increases ECM production, and inhibits endochondral ossification.
The three isotypes of TGF-β (β1, β2, and β3) are secreted in their inactive form and are acti-
vated only when dissociated from a peptide associated with latency (LAP). TGF-β initiates 
signaling by binding to the serine/threonine kinase types I and II receptors on the cell surface, 
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which then propagates the signal through the phosphorylation of the R-Smad protein (Smad 
2 and 3). TGF-β signaling is also negatively regulated by I-Smad (Smad 6 and 7), which inter-
feres with R-Smad phosphorylation. TGF-β also activates mitogen-activated protein kinases 
(MAPK) [74].
BMPs are also multifunctional polypeptides having a key role in chondrogenesis by promot-
ing terminal differentiation [76]. During first stages of chondrogenesis, the BMPs induce the 
expression of the N-cadherin thus promoting cell-cell interaction [77] indispensable for SOX 
expression. BMP signalling pathway enhances type X collagen promoter activity resulting in 
chondrocyte hypertrophy [78]. Furthermore, in vitro culturing BMP promotes the up-regula-
tion of type II collagen and aggrecan [79].
4.2.3. Fibroblast growth factors
Fibroblast growth factors (FGF) belong to a family of polypeptides that are involved in several 
functions including cell proliferation, differentiation, survival, and motility, essential during 
cartilage growth, development, and repair. FGFs play a crucial role in the maintenance of 
stem cells and their activation [80]. FGF binding to fibroblast growth factor receptor (FGFR) 
leads to the activation of signaling pathways, including PI3K, Src, phospholipase Cγ, MAPKs, 
ERK, and p38. In particular, two members of the FGF family, basic fibroblast growth factor 
(bFGF, also known as FGF-2) and fibroblast growth factor-18 (FGF-18), play an important 
regulatory role in maintaining homeostasis of the cartilage matrix [74].
4.2.4. Vascular endothelial growth factor
Vascular endothelial growth factor (VEGF) is a hormone that seems to be important in the 
cartilage growth plate, where it supports the formation of endochondral bone, apparently by 
attracting endothelial cells from the bone marrow. It has been speculated that this factor could 
promote the mitotic cycle of chondrocytes, although little is known about this feature [81].
4.2.5. Platelet-derived growth factor
Platelet-derived growth factor (PDGF) is a potent mitogenic and chemotactic factor for all cells 
of mesenchymal origin, including chondrocytes and mesenchymal stem cells. It is related to 
increased cell proliferation and proteoglycan production [82].
4.2.6. Transcription factors
Many transcription factors are involved during chondrogenesis and endochondral ossifica-
tion depending on the location of the chondrocytes within the articular cartilage. There are 
three main transcription factors involved in chondrogenesis: Sox9, L-Sox5, and Sox6.
Sox9 is involved in the condensation phase of MSCs into prechondrocytes when it is expressed 
in cells that initiate an aggregation that afterward stimulates the expression of cartilage-
specific markers and inhibits terminal differentiation of chondrocytes. Sox9 also induces the 
expression of the L-SOX5 and SOX6 transcription factors, which definitely compromise the 
MSCs to develop in the chondrogenic lineage [83].
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4.3. Scaffolds
4.3.1. Biomaterials
A significant research has been focused toward developing biomaterials that can mimic car-
tilage matrix, thus restoring function at the defect site. The biomaterials should satisfy three 
significant criteria: mechanical properties according to those of existing cartilage, integration 
with adjacent cartilage, and adequate biodegradability.
Natural biomaterials have the advantage as better cellular interaction due to the presence of 
ligands that can facilitate adhesion, in addition to promoting the activation of various chon-
drogenic activation pathways. The most common natural biomaterials are collagen, gelatine, 
lysozyme, Matrigel™, hyaluronic acid, fibrin, chitosan, agarose, and alginate [84].
As chondrocytes are surrounded by a hyaluronan-based pericellular matrix, they have been 
designed as hydrogels consisting of hyaluronan [85]. Chondrocytes attach firmly to hyaluro-
nan-based matrices, stimulating as a result the matrix production [86]. Despite these advan-
tages, the newly formed matrix is characterized by insufficient mechanical integrity [87].
Alginate is a natural biopolymer derived from brown algae and is composed of homopol-
ymeric blocks of L-glucuronic acid and D-manuronic acid [88] and is widely used in bio-
medicine due to its biocompatibility and low toxicity [89]. Such materials require the use of 
divalent gelling cations to form a network structure, which allows the cells used to promote 
tissue regeneration to be trapped [90].
In contrast to natural polymers, synthetic polymers provide a better control of the structural 
and mechanical features. Polyglycolic acid (PGA) and polylactic acid (PLA) are the most used 
since they degrade by hydrolysis at rates depending on the selecting monomers [91]. A major 
disadvantage of synthetic polymers is that they do not offer specific biological functions [92]. 
Its functionalization with biological motifs or bioactive molecules facilitates cell adhesion and 
consequently stimulating matrix production [76].
Fragments derived from the cartilage have been also used for application in joint regen-
eration; however, it is mandatory to eliminate the cellular component to avoid an immune 
response when implanted in an in vivo model; therefore, they are decellularized by different 
methods [93, 94]. It has been observed that they support the production of type II collagen and 
proteoglycans; in addition, they minimize the hypertrophy of the newly formed tissues with 
the cooperation of growth factors [95].
4.3.2. Biological scaffolds and its use in the treatment of chondral lesions
A better understanding of the molecular structure and functional role of extracellular matrix 
components in the physiology of the cartilage [96] supported the construction of scaffolds 
which mimick cartilage microenvironment.
Scaffold-based approaches possess several advantages compared to scaffold-free: such as 
increased control to fill the cartilage defect according to the features and size of the lesion; 
no surgical procedures are required to obtain tissue from the patient; increased graft stabil-
ity that influence recovery time for the patient. Most important, since the chondrocytes are 
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cultured in a 3D environment, dedifferentiation is a minimal concern, thus, the cells are able 
to produce a more hyaline-like cartilage [97].
The geometry and microarchitecture of scaffolds are important factors that determine cell 
adhesion and migration, as well as the preservation of the synthesized matrix. [98]. In addi-
tion, the pore size is a critical feature; it should be large enough to allow the migration of the 
cells and thus promote the production of ECM, [99] but small enough to establish a large sur-
face area for cell adhesion. It is recommended to generate scaffolds with a pore size ranging 
between 300 and 350 nm [100].
Successful cartilage regeneration is closely related to the ability of the scaffold to support the 
chondrocyte proliferation rate and to the differentiation of MSCs within a tissue-engineered 
3D matrix [101]. At the same time, it becomes imperative to characterize the quality of the 
expanded MSC as well as to avert the development of hypertrophic chondrocytes [49, 102].
5. Minimizing the development of hypertrophic tissue in cell-based 
therapies
Chondrogenic hypertrophy is characterized by an increase of the cell volume as well as remod-
eling of ECM [103]. The increase in the volume is the result of intracellular and extracellular 
osmolarity variations where aggrecans are the main contributors.
The hypertrophic differentiation of chondrocytes is a process that gradually leads to the min-
eralization of cartilage. The main factors involved are the transcription factor runt-related 
transcription factor 2 (RUNX2) and myocyte enhancer factor-2C (MEF2C). Both promote the 
expression of proteins that determine terminal differentiation, including matrix metallopro-
teinase 13 (MMP13) [104], type X collagen [105], alkaline phosphatase (ALP), and vascular 
endothelial growth factor (VEGF) [106]; all of them functionally contribute to endochondral 
ossification. MMP13 is a key modulator in this process as it degrades type II collagen and 
aggrecan [107]. Furthermore, type X collagen serves as a framework for the calcification 
through matrix vesicles [108], ALP hydrolyzes pyrophosphate to inorganic phosphate that, in 
the presence of calcium, forms hydroxyapatite (Figure 2) [109].
Among the growth factors that are directly involved in the process are transforming growth 
factors (TGFs) and bone morphogenetic proteins, which are able to initiate cartilage differen-
tiation but often lead to hypertrophy and calcification, since TGFβ3 is also the active signal 
pathway during endochondral ossification [110].
Moreover, Woods et al. has reported that Rac1 functions as a positive regulator in governing 
chondrocyte hypertrophy, maturation, and calcification [111] through up-regulation of type X 
collagen, MMP13, and ADTAMTS-5 that induce hypertrophy and chondrocyte calcification [112].
Therefore, Rac1 is an important target for controlling the development of hypertrophy has 
been demonstrated that the inhibition of Rac1 activity overcomes not only chondrocyte 
hypertrophy and calcification but also alleviates osteoarthritis progression [56, 112–115].
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TGF-βs and BMPs bind to specific receptors to recruit type I receptor to trigger signalling of 
their specific receptor-Smads. The importance of Smad-dependent TGF-β- and BMP-signalling 
pathways for cartilage and bone formation has been well established whose synergic or antag-
onistic function depends on the microenvironment [116].
However, the control of the activity of some members of the TGF superfamily as TGF-β1 is 
important to control the subsequent maturation of chondrocytes and the consequent miner-
alization [117]. TGFβ1 is a key factor in the maintenance of chondrocyte phenotype. BMP9 
and TGFβ1 dose-dependently synergized on Smad2 phosphorylation and showed an addi-
tive effect on expression of Smad3-dependent genes. Furthermore, the addition of a low dose 
of TGFβ1 (1 ng/ml) diminishes expression of early markers of cellular hypertrophy Alpl and 
type X collagen (Figure 2) [118, 119].
Likewise, in vitro addition of TGFβ3 in the later stages of differentiation has been shown to 
control the fibrotic process. Pei et al. found that in synovium-derived stem cells (SDSCs), 
TGF-β3 enhancing collagen II and sulfated glycosaminoglycan minimize the expression of 
collagen I in the repair of partial-thickness cartilage defects in porcine SDSC pellets compared 
with TGF-β1 [120].
Meanwhile, blocking of BMP signalling during chondrogenesis of MSC restricts Type X col-
lagen and MMP13 expression from cartilage at maintained collagen type II and enhanced 
SOX9 expression [116]. Thus, the manipulation of BMP-signalling (essentially BMP4) is able 
to shift chondrogenesis of the MSCs toward a nonhypertrophic phenotype. Dexheimer et al. 
addressed this concern by the inhibition of Smad1/5/9-signalling using dorsomorphin [121]. 
This seems to be a good strategy to potentiate chondrogenesis and also inhibit hypertrophic 
differentiation; however, now the efforts should be focused on establishing a timeline on spe-
cific cellular models at which point the inhibition of pSmad1/5/9 signaling should be carried 
out. Inhibition of pSmad1/5/9 signalling apparently stopped chondrogenesis or decelerated 
MSC differentiation toward hypertrophy depending on the time of treatment initiation.
FGF factors play an important regulatory role in maintaining homeostasis of the cartilage 
matrix [74, 164]. Correa et al. designed an elegant sequential protocol based on the addition 
of FGF2, 9, and 18 on bone marrow–derived hMSC. The growth factors are added as follows: 
increased cell proliferation and priming (FGF2 [d0 to d3]); stimulated early chondrogenic dif-
ferentiation by shifting the chondrogenic program earlier (TGF-β, FGF9/FGF18 [d4 to d14]); 
enhanced ECM production (d14 to d21); and delayed terminal hypertrophy (FGF9/FGF18 
[d21 to d28]). To highlight, in the proterminally differentiating conditions, both FGF9 and 
FGF18 were able to reduce Runx2 expression and the activity of the hypertrophy-specific 
marker alkaline phosphatase (ALP) (Figure 2) [122].
As has already been established, TGF-β and bone morphogenetic protein are key factors for chon-
drogenesis. They are capable of initiating signals in mitogen-activated protein kinase (MAPK) 
pathway essentially of extracellular signal-regulated kinase ERK-1 and ERK-2 [123, 124].
PD98059 is one of the ERK inhibitors that suppressed hypertrophy in the chondrogenesis from 
bone marrow–derived hMSCs, inhibiting the cascade signalling upstream of ERK1/2 activa-
tion [125, 126]. Lee et al. [123] constructed a PD98059-impregnated poly(lactic-co-glycolic acid) 
Current Applications of Mesenchymal Stem Cells for Cartilage Tissue Engineering
http://dx.doi.org/ 10.5772/intechopen.68172
165
(PLGA) scaffold and demonstrated that it effectively suppresses the hypertrophy of hBM-
MSCs that have been differentiated toward the chondrocytic lineage in basic chondrogenic 
medium (Dulbecco’s modified Eagle’s medium/Ham’s F-12 nutrient mixture: DMEM/F-12 
supplemented with 1% insulin-transferrin-sodium selenite [ITS], 50 μM ascorbate-2-phos-
phate, 1×10−7 M dexamethasone, 1 mM sodium pyruvate, and 50 μM l-proline). The efficiency 
of the system was challenged in a rabbit model where the main observations were the abun-
dant presence of type-II collagen in ECM with the absence of types I and type X collagens [123].
As described in the above example, scaffolds can additionally be a useful tool for the release 
of elements that both regulate the differentiation process and control the development of 
fibrotic tissue. Inhibitors are not the only elements that can be incorporated into scaffolding 
systems; the addition of growth factors to scaffold systems has also been reported to reduce 
the development of hypertrophic chondrocytes, with successful results.
Mimicking the native tissue architecture is critical for effective cartilage regeneration. Kim 
et al. developed a multifunctional system based on TGF-β3 encapsulated PLCL scaffold 
using human adipose-derived stem cells (ADSCs) to promote chondrogenesis. They dem-
onstrated the release of TGF-β3 molecules for 8 weeks, which remained in the PLCL matrix. 
Furthermore, this scaffolding system formed a hyaline cartilage-specific lacunae structure 
and minimized the hypertrophy of differentiated chondrocytes [127].
Fibrocartilage is a dense, fibrous version of a cartilage. It has been shown that a lack of inte-
gration of the graft in the lesion area promotes poor functional properties and limits complete 
regeneration of the defect.
The scaffold design should offer hierarchical structure, desired mechanical properties (stiffness, 
elasticity, permeability, and diffusion), and ability for adapting into the anatomical shapes. The 
use of scaffolds that are composed of one type of biomaterial, with homogeneous porosity and 
architecture, and used a single-cell type limits the integration with the surrounding tissue and 
encourages a fibrotic process. Instead, the design of stratified or gradient scaffold mimics the 
structural and mechanical features of a native osteochondral unit. In order to achieve stratifi-
cation and composition, composite scaffolds are assembled through a multilayered scaffold 
design; in this way, structural templates for the cartilaginous layer, the tidemark, and calcified 
cartilage, and the subchondral bone are generated [163].
A biphasic scaffold design was reported, based on a silk-protein scaffold constituting the 
cartilage phase and a silk-coated strontium-hardystonite-gahnite ceramic scaffold constitut-
ing the bone phase, and both phases are cellularized with human mesenchymal stem cells 
(hMSCs). For the biphasic scaffold, there were noticeable to significant increases in Sox-9, 
collagen type II, and aggrecan in addition to low type X collagen expression levels compared 
with the chondral single-phase version of the implant [39].
Ho et al. designed a biphasic implant comprising of a polycaprolactone (PCL) cartilage scaffold 
and a PCL-tricalcium phosphate as bone scaffold; it was seeded with mesenchymal stem cells 
(MSCs), and the cartilage and bone constructs were maintained in the MSC expansion media 
prior to implantation into critically sized osteochondral defects in a pig model. After 6 months, 
the cartilaginous repair was observed with a low occurrence of fibrocartilage. Furthermore, 
the functional cartilage restoration was demonstrated by a high Young’s modulus [40].
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The chondral phase was derived from bovine decellularized articular cartilage ECM, while 
the osseous phase was composed of a PLGA/β-TCP wrapped with type I collagen. The bipha-
sic scaffolds was cellularized by BMSCs induced with chondrogenic and osteogenic medium 
and implanted into osteochondral defects in a rabbit knee model. By a histological evaluation, 
the presence of an uniform neocartilage surface, a clear fusion of neocartilage, a regenerated 
subchondral bone with a well-defined tidemark, and no evidence of fibrocartilage was dem-
onstrated [41].
6. The efficacy and safety of different treatments of cartilage in current 
clinical trials
Current surgical treatments for symptomatic cartilage lesions include reparative and recon-
structive treatments. The former employ techniques that stimulate tissue cells to form hya-
line cartilage, such as the microfracture technique, perforation, abrasion arthroplasty, and 
biological procedures involving cell culture, such as autologous chondrocyte implantation 
(ACI), of the latter derives the development of biocompatible three-dimensional scaffolds, 
where chondrocytes, stem cells, or chondrocyte-like cells can be grown. The latter involves 
mosaicplasty, such as the transplantation of autografts or allografts, which are composed 
of mature hyaline cartilage attached to the subchondral bone [128]. The type of treatment 
to be used will depend on the size of the lesion, the location, and the type of activity of the 
patient.
ACI has been the treatment most often used to treat large knee cartilage injuries. Previous 
studies have compared ACI with mosaicplasty, microfracture, and matrix-guided microfrac-
ture; where the ACI obtains better results (88%) than mosaicplasty (69%), presenting hyaline 
cartilage in half of the biopsies; however, statistically significant results are restricted to the 
medial condylar area [129]. ACI has been compared to microfracture and mosaicplasty but 
has never been compared with simple arthroscopic debridement and rehabilitation alone. At 
present, the first study that will detail, with a high level of evidence, the results of comparing 
ACI with simple debridement and physiotherapy in symptomatic lesions of full thickness of 
the knee is being carried out. This study aims to increase the clinical and economic knowledge 
between these techniques in the short and long term [130].
Recently, surgical treatments have been complemented with the use of autologous biological 
materials such as PRP and mesenchymal stem cells [162]. Recently, the use of autologous PRP 
coupled with the microfracture technique has been associated with better short-term clinical 
and functional outcomes, especially in pain [131–133]; in addition, arthroscopic implantation of 
AD-MSC combined with the microfracture technique has also been associated with a decrease 
in pain [134]. Similarly, the use of AD-MSC [135, 136] or BM-MSC [137, 138] has been reported 
as a safe therapeutic alternative via intraarticular injection in patients with osteoarthritis, 
which report a significant improvement in pain levels. Another complementary therapy is the 
use of hyaluronic acid, which improves articular cartilage repair in combination with autolo-
gous peripheral blood stem cells via intraarticular postoperative injection, complementing the 
technique of arthroscopic subchondral perforation [139].
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Gene therapy techniques represent an alternative strategy for gene transfer for therapeutic pur-
poses. Through gene therapy, proteins are synthesized at the site of the defect or injury where 
they directly influence the natural microenvironment. Growth factors most frequently synthe-
sized by engineered cartilage cells to regenerate damaged cartilage include BMPs, IGF-1, and 
TGF-βs 1, 2, and 3.
The application of genetically engineered cartilage in clinical trials begins to generate results. 
Mont et al. have reported on a series of clinical trials in which the effect of injecting genetically 
engineered chondrocytes virally transduced with TGF-β1 (GEC-TGF-β1) into the knees of 54 
patients with osteoarthritis has been evaluated. After 12 or 24 weeks of treatment, patients 
reported a degenerative process delayed compared to the placebo. It should be noted that the 
studies demonstrating cartilage regeneration are missing [140].
Moreover, they also evaluate the efficacy to safely regenerate cartilage by a phase II clini-
cal trial in 102 (ClinicalTrials.gov NCT01221441) [141] and 27 patients (ClinicalTrials.gov 
NCT02341378) [142], respectively. Patients expressed decreased pain and improvement in 
function and physical capacity; thus, treatment injection of GEC-TGF-β1 seems to improve 
symptoms and pain due to knee osteoarthritis.
Although gene therapy is very promising for cartilage repair, much remains to be understood 
about the clinical results obtained. It is crucial to control several aspects such as the duration 
of transgenic expression, as well as the identification and selection of a therapeutic factor that 
is clinically useful for cartilage regeneration.
With the boom in tissue engineering in recent years and innovation in the area of biomaterials, 
doctors have new options for treating chondral lesions. To date, the clinical use of these mate-
rials is limited; very few polymers have been used for clinical trials in cartilage tissue engineer-
ing. The list includes collagen, polymers based on hyaluronan and fibrin, because they have a 
biomimetic structure similar to the native articular cartilage. Chondral or osteochondral grafts 
consist in the surgical transfer of mature tissue to a cartilage defect. The graft could be an 
autologous tissue transfer from a nonload-bearing zone and cultivated on a porated scaffold.
Within this narrow list is highlighted the collagen, which is the main component of ECM. 
Zheng et al. have analyzed the efficacy of an implant constructed with chondrocytes cultured 
onto collagen type I/III scaffolds in 56 patients with OA. The results mainly evidenced the 
maintenance of a chondrocytic phenotype, as well as a good integration of the implant in the 
injured area and the production of aggrecan and type II collagen. These data demonstrated 
the regeneration of hyaline cartilage tissue 6 months after treatment [143]. Furthermore, based 
on the information contained in the website, clinicaltrials.gov, clinical trials using stem cells 
cultivated mainly on collagen scaffolds are ongoing.
Assor et al. conduct a clinical trial to demonstrate the efficacy and safety of BM-MSCs cul-
tured on a collagen type I scaffold dotted with hydroxyapatite to regenerate articular cartilage 
defects of the knee (Table 1 NCT01159899). Otherwise, Giannini et al. studied the critical 
points of the regenerative treatment with BM-MSCs embedded in equine collagen type I scaf-
fold (Table 1 NCT02005861). Both trials are still in process and have not shown final results.
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Clinical trials.gov 
identifier
Phase Brief description Status No. patients Principal 
investigator
NCT00850187 Phase 1 Autologous 
transplantation 
of mesenchymal 
stem cells (MSCs) 
cultured on a 
collagen I scaffold 
in full-thickness 
articular cartilage
Completed 6 Leila 
Taghiyar,
NCT01159899 Early Phase 1 Autologous 
BM-MSCs, 
stimulated 
with a protein 
matrix cultured 
in a collagen 
hydroxyapatite 
scaffold
Unknown 50 Michel Assor
NCT02005861 Not provided Bone marrow 
aspirate concentrate 
cultivated onto an 
equine collagen 




Recruiting 140 Sandro 
Giannini
NCT02659215 Not provided Bone marrow 
aspirate concentrate 






NCT01282034 Phase 4 Bioceramic, 
multilayered 






Completed 145 Maurilio 
Marcacci
NCT01471236 Phase 4 A cell-free system 
based on a biphasic, 
porous resorbable 
scaffold. Cartilage 
phase consist in a 
modified aragonite 
and HA, while bone 
phase in aragonite 
(Agili-C implant).
Recruiting 65 Elizaveta Kon
Source: https://clinicaltrials.gov.
Table 1. Current clinical trials based on cartilage tissue engineered approaches for the treatment of chondral and 
osteochondral diseases.
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Hyaluronate is also reported in the clinical trials; Gobbi leads a study to evaluate the efficiency 
of Hyalofast®, together with bone marrow aspirate containing the MSCs without the need for 
processes for cell isolation and ex vivo expansion. This methodology has the disadvantage that 
the number of MSCs destined for the repair of the chondral tissue is not controlled nor the 
cellularity of the aspirate (Table 1 NCT02659215).
New studies evaluate the performance, stability, safety, and viability of the surgical proce-
dure using biomimetic osteochondral implants. One of the most studied and relevant proce-
dure that is currently marketed as MaioRegen® (Table 1 NCT01471236); this is a three-phase 
implant that considers the biomechanics of the chondral phase, the tidemark, and subchon-
dral bone. Its composition is based on a collagen type-I hydroxyapatite gradient. MaioRegen® 
has demonstrated throughout its clinical studies that its technique is safe and that the clinical 
results in the short- and medium-term follow-up are effective in a large population of patients 
[144–148], even attributed better results than other commercial scaffolds ChondroMimeticTM 
[149] and TruFit CBTM [11, 150–152]. Despite the encouraging in vitro results of a wide variety 
of osteochondral scaffolds, most are in the early stages of development.
In general, clinical trials present current techniques for treating chondral lesions as safe. 
However, in order to determine the best surgical option in the treatment of symptomatic 
chondral defects, a rigorous clinical trial should be developed, where there is prospective 
control, randomization control, even feeding control, and rehabilitation control so that on the 
basis of comparative results, the surgeon provides an effective treatment.
7. Conclusion
This chapter presents an overview of the advances in the design of new cell-based therapies 
in conjunction with the tools that the tissue engineering offers, such as the use of bioma-
terials, the selection of subpopulations, and the addition in a temporal manner of growth 
factors.
It is important to emphasize that the understanding of the molecular mechanisms that governs 
the chondrocyte differentiation allows generating strategies that reflect a balance between the 
chondrocyte maturation and the containment in the development of fibrotic repair tissue.
Indeed, the therapeutic approaches for the repair and regeneration of joint tissue should con-
sider as a goal mimic the osteochondral structure, which will result in an effective and safe 
clinical application.
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Abbreviations
ACI autologous chondrocyte implantation
AD-MSCs adipose tissue-derived MSCs
ALP alkaline phosphatase
ACT autologous implantation of chondrocytes
BM-MSCs bone marrow-derived stem cells
BMP bone morphogenic protein
ECM extracellular matrix
ERK1/2 extracellular signal-regulated kinase -1 and -2
FGF fibroblast growth factor
FGFR fibroblast growth factor receptor
GAGs glycosaminoglycan
ICRS International Cartilage Repair Society
IGF insulin-like growth factor
LAP latency-associated peptide
MMP13 matrix metalloproteinase 13
MSCs mesenchymal stem cells
MAPK mitogen-activated protein kinases
MEF2C myocyte enhancer factor-2C
OA osteoarthritis








RUNX2 Runt-related transcription factor 2
SDSCS synovium-derived MSCs
TI tissue engineering
TGF-β transforming growth factor-β
VEGF vascular endothelial growth factor
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